Banook, a global leader in clinical trial services, has acquired FLUIDDA, a pioneer in Functional Respiratory Imaging (FRI), for an undisclosed amount. This acquisition significantly expands Banook's capabilities within the respiratory clinical research sector. FLUIDDA specializes in developing imaging biomarkers that combine biomedical imaging, such as HRCT scans, and advanced engineering methods, including Computational Fluid Dynamics. This innovative approach yields sensitive outcome parameters to detect physiological changes, offering additional insight into therapeutic interventions to optimize therapy and improve patient selection.
FLUIDDA is recognized as a world leader in Functional Respiratory Imaging. Its proprietary FRI technology aims to make clinical trials shorter, faster, and more cost-effective, while also supporting personalized medicine by optimizing diagnosis, monitoring disease progression, and the effects of therapy. Beyond its technology development, FLUIDDA provides comprehensive CRO services with a specialized focus on imaging, offering clients support from initial protocol writing through to full data analysis using its advanced processing techniques.
The acquisition is strategically significant for Banook, integrating FLUIDDA’s unique imaging and artificial intelligence expertise directly into its existing global clinical trial framework. By combining FLUIDDA's specialized technology and scientific acumen with Banook’s established operational excellence and worldwide presence, the merged entity aims to offer an unparalleled service to pharmaceutical and biotech companies developing treatments for respiratory diseases. This synergy is expected to accelerate drug development, streamline clinical pathways, and ultimately enhance patient care.
This corporate acquisition underscores a commitment to advancing respiratory clinical research. The integration of FLUIDDA's specialized imaging solutions with Banook's global service infrastructure is anticipated to create a more robust and comprehensive partner, driving innovation in treatment pathways, reducing healthcare costs, and bringing new therapies to market more rapidly. The combined operations are poised to strengthen their position in delivering cutting-edge solutions for patients worldwide.